Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor

Abstract

Topical INCB018424 dosed for 28 days QD or BID is pharmacologically active in patients with active psoriasis and modulates proinflammatory cytokines in the pathogenesis of psoriatic lesions.